Supplemental Cash Flow Information (Tables)

9 Months Ended

Sep. 30, 2025

The reconciliation of net income (loss) to net cash provided by operating activities is as follows (in millions):


	Nine Months Ended
	September 30,
	2025		2024
Net income (loss)	$	39.9	$	(1,128.4)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	122.9		112.4
Reduction in the carrying amount of right-of-use assets	30.1		31.1
Share-based compensation	42.1		45.9
Acquired in-process research and development	—		29.5
Other-than-temporary impairment loss on investments	6.0		—
Current expected credit losses on loans	1.4		—
Losses from change in fair market value of equity securities and loan receivable	129.1		1,680.3

Changes in fair value of contingent consideration	0.6		0.8
Payments for operating lease liabilities	(34.0)		(32.2)
Decrease in accounts receivable	15.7		25.6
(Increase) decrease in inventories	17.3		(16.0)
(Increase) decrease in other current assets	16.4		(4.7)
Increase (decrease) in accounts payable and other current liabilities	1.2		(24.4)
Increase (decrease) in income taxes payable	(12.1)		21.8
Decrease in deferred income taxes	(19.7)		(408.5)
Increase (decrease) in other long-term liabilities	(0.5)		1.4
Other	10.9		(3.6)
Net cash provided by operating activities	$	367.3	$	331.0

Non-cash investing activities:
Purchased property, plant and equipment	$	6.5	$	7.4
Purchased marketable securities and investments	$	3.3	$	5.7
Sold marketable securities and investments	$	—	$	0.2

BIO-RAD LABORATORIES, INC. 10-Q